Biologics Reached Record Share Of Novel Approvals In 2009
The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
You may also be interested in...
The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.
Centocor Ortho Biotech's Stelara (ustekinumab) brings a novel mechanism and superior efficacy to the plaque psoriasis marketplace, but in terms of risk management, the anti-inflammatory biologic differs little from the tumor necrosis factor inhibitor class
Here comes the swine flu again, but this time tens of millions of people could be immunized thanks to the first round of vaccines due in mid-October